A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer

• Publication date

  2002-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.10239PMID 11900215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Octreotide

  2025cited by this paper
• Octreotide as first-line treatment for women with metastatic breast cancer

  2004cited by this paper
• Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.

  2001cited by this paper
• Interim monitoring of clinical trials based on long-term binary endpoints.

  2001cited by this paper
• Bayesian monitoring of phase II trials in cancer chemoprevention.

  1999cited by this paper
• A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

  1999cited by this paper
• Mechanisms of Antineoplastic Action of Somatostatin Analogs

  1998cited by this paper
• Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

  1997cited by this paper
• Octreotide.

  1996cited by this paper
• Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered on four prospective clinical trials

  1996cited by this paper
• Insulin-like Growth Factors and Cancer

  1995cited by this paper
• Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer

  1995cited by this paper
• Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas.

  1994cited by this paper
• Some practical aspects of the interim monitoring of clinical trials.

  1994cited by this paper
• Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer.

  1993cited by this paper
• Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995).

  1992cited by this paper
• The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

  1991cited by this paper
• Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane.

  1991cited by this paper
• Adjuvant Therapy of Cancer

  1990cited by this paper
• Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.

  1990cited by this paper
• The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer

  1989cited by this paper
• Oncological applications of somatostatin analogues.

  1988cited by this paper
• Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells.

  1988cited by this paper
• Growth regulation of human breast carcinoma occurs through regulated growth factor secretion

  1987cited by this paper
• Characterization of estrogen responsive transforming activity in human breast cancer cell lines.

  1986cited by this paper

• Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors

  2025cites this paper
• Somatostatin and Somatostatin Receptors in Tumour Biology

  2023cites this paper
• The effects of fulvestrant treatment on hormone receptor-positive metastatic breast cancer

  2019cites this paper
• Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.

  2019cites this paper
• Fulvestrant Efficacy in Artificial Menopausal Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Patients under 50 Years Old

  2018cites this paper
• Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.

  2017cites this paper
• Preclinical evaluation of somatostatin analogues for breast cancer imaging using positron emission tomography.

  2017cites this paper
• Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode

  2016cites this paper
• Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer.

  2014cites this paper
• Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

  2014cites this paper
• A review of the use of somatostatin analogs in oncology

  2013cites this paper
• Somatostatin receptors: from signaling to clinical practice.

  2013cites this paper
• Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model.

  2013cites this paper
• Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm

  2013cites this paper
• Adjuvant systemic therapy for early breast cancer

  2012cites this paper
• Differential Expression of Somatostatin Receptor Subtype 1–5 Proteins in Numerous Human Normal Tissues

  2012cites this paper
• Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

  2012cites this paper
• [Somatostatin in breast cancer].

  2011cites this paper
• Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.

  2011cites this paper
• Somatostatin and somatostatin receptors: from basic concepts to clinical applications.

  2010cites this paper
• Tubulin-targeting agents in hybrid drugs.

  2010cites this paper
• The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

  2009cites this paper
• Biology of somatostatin in breast cancer.

  2008cites this paper
• Functional assessment of gastroenteropancreatic neuroendocrine tumor’s (GEP-NET) sensitivity to bio- and chemotherapeutic drugs and the role of survivin and aurora kinase B expression in GEP-NET disease

  2008cites this paper
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

  2008cites this paper
• Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment

  2007cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 216 Midgut Carcinoid Tumours New Diagnostic Procedures and Treatment

  2007cites this paper
• Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.

  2005cites this paper
• Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells

  2005cites this paper
• The puzzle of somatostatin: action, receptors, analogues and therapy.

  2005cites this paper
• Somatostatin receptors in non-endocrine tumours.

  2004cites this paper
• Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue.

  2004cites this paper
• The insulin-like growth factor system in advanced breast cancer.

  2004cites this paper
• Anti-insulin-like growth factor strategies in breast cancer.

  2004cites this paper
• Novel modalities of somatostatin actions.

  2004cites this paper
• Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.

  2004cites this paper
• Exploiting the hallmarks of cancer: the future conquest of breast cancer.

  2003cites this paper
• The pipeline of new anticancer agents for breast cancer treatment in 2003.

  2003cites this paper
• The GH-IGF-I axis and breast cancer.

  2003cites this paper
• IGF-I: from diagnostic to triple-helix gene therapy of solid tumors.

  2002cites this paper
• [Somatostatin receptors in non-endocrine tumours].

  2001cites this paper